Clear Search

Showing 3 results for “Roth DA” published 2022.

November 2022

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.

more…

May 2022

Impact of belimumab on organ damage in systemic lupus erythematosus

Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901

Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.

more…

March 2022